Asia Pacific Diabetes Care Devices Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Asia Pacific Diabetes Care Devices Market Overview

Diabetes care devices are witnessing significant technological advancements that improve disease monitoring, treatment efficiency, and patient engagement. Expanding healthcare access is supporting broader adoption across the region. The market is driven by rapid urbanization, increasing healthcare investments, rising diabetes prevalence, and expanding availability of advanced medical devices. The market is poised to reach USD 25.32 Billion by 2035.

Asia Pacific Diabetes Care Devices Market Growth Analysis and Key Influencers

Asia Pacific Diabetes Care Devices Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Asia Pacific Diabetes Care Devices Market Growth Drivers

AI-Enabled Continuous Glucose Monitoring Accelerates Market Value

The market is witnessing significant growth driven by the increasing adoption of artificial intelligence (AI)-enabled continuous glucose monitoring (CGM) systems and integrated digital diabetes management solutions. These technologies improve glucose monitoring accuracy, enable predictive insights, and support proactive disease management, thereby enhancing patient outcomes and treatment adherence. For instance, in September 2025, Roche announced the integration of its AI-enabled Accu-Chek SmartGuide CGM with the mySugr application and expanded its availability across Asia-Pacific. The real-world evidence presented demonstrated a reduction in nighttime hypoglycemia risk, highlighting the growing demand for intelligent diabetes care technologies and supporting sustained market expansion.

Asia Pacific Diabetes Care Devices Market Restraints

Counterfeit Diabetes Care Devices Limit Market Expansion

The market is challenged by the increasing circulation of counterfeit diabetes care devices, which can compromise diagnostic accuracy, patient safety, and confidence in branded products. The availability of substandard devices also creates regulatory concerns and discourages the adoption of advanced diabetes management technologies. For example, in June 2024, CNBC reported that Roche filed a lawsuit alleging the sale of counterfeit Accu-Chek diabetes devices that could provide inaccurate blood glucose readings and increase the risk of serious health complications. Such incidents are expected to impede market expansion by undermining product reliability and consumer trust.

Asia Pacific Diabetes Care Devices Market Opportunities

Affordable Indigenous Glucose Monitoring Innovations Create New Market Potential

The market is expected to benefit from the growing development of affordable, patient-centric glucose monitoring technologies that improve accessibility and encourage regular diabetes management. Cost-effective innovations are particularly important in emerging economies, where affordability remains a key consideration for device adoption. For instance, in November 2025, researchers at the Indian Institute of Technology Madras developed and patented a minimally invasive, cost-effective continuous glucose monitoring device featuring reusable electronics and a disposable microneedle sensor. This innovation is anticipated to improve access to advanced diabetes care while supporting local manufacturing and long-term market development.

Asia Pacific Diabetes Care Devices Market Trends

The market is witnessing several trends, including AI-enabled diabetes management, connected glucose monitoring systems, and integrated digital health solutions.

Integration of AI-Powered Digital Diabetes Management Solutions Enhances Market Value

The market is increasingly shifting toward connected diabetes care ecosystems that integrate blood glucose monitoring devices with artificial intelligence-driven digital health platforms. These integrated solutions enable personalized disease management, real-time monitoring, and data-driven clinical decision-making, improving patient engagement and treatment outcomes. For instance, in March 2023, Astellas Pharma partnered with Roche Diabetes Care Japan to develop and commercialize an integrated diabetes self-management solution combining the Accu-Chek Guide Me glucose monitoring system with the BlueStar digital platform. This trend is expected to accelerate digital transformation and strengthen long-term market growth.

Asia Pacific Diabetes Care Devices Market Share

Blood Glucose Monitoring Systems are Expected to Dominate the Market by Product Type

The market is segmented by product type into blood glucose monitoring systems, insulin delivery devices, diabetes management mobile applications. Among these, blood glucose monitoring systems are expected to account for the largest market share owing to continuous technological innovation, increasing demand for convenient glucose monitoring, and the growing adoption of non-invasive solutions. For example, in February 2026, TAMRON invested in Light Touch Technology to support the commercialization of the world's first needle-free, non-invasive blood glucose sensor. Such technological advancements are expected to strengthen product adoption and reinforce the segment's market leadership.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Asia Pacific Diabetes Care Devices Market Analysis by Region

The regions covered in the report include China, Japan, India, ASEAN, Australia, and others. Among these, China is expected to lead the market due to its large diabetic population, robust healthcare infrastructure, rapid digital healthcare adoption, and increasing availability of innovative diabetes therapies. For instance, in July 2026, Fangzhou launched Novo Nordisk's once-weekly basal insulin/GLP-1 therapy, Kyinsu®, on its AI-enabled Internet hospital platform to improve patient access and long-term chronic disease management. Such strategic initiatives are expected to further strengthen China's leading position in the market.

Leading Players in the Asia Pacific Diabetes Care Devices Market

Asia Pacific Diabetes Care Devices Market Segmentation

Key Questions Answered in the Asia Pacific Diabetes Care Devices Market Report

• What was the Asia Pacific diabetes care devices market value in 2025?
• What is the Asia Pacific diabetes care devices market forecast outlook for 2026-2035?
• What are the major factors aiding the Asia Pacific diabetes care devices market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major diabetes care devices market trends?
• Which product type is expected to dominate the market segment?
• Which disease type is projected to lead the market segment?
• Which patient care setting is anticipated to drive the market segment?
• Who are the key players involved in the Asia Pacific diabetes care devices market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews conducted with 30+ endocrinologists, diabetologists, diabetes educators, hospital procurement managers, medical device distributors, and payer representatives across China, Japan, India, Australia, and ASEAN countries, including key opinion leaders (KOLs) from leading diabetes associations, hospitals, and academic institutions.
• Secondary Research: Peer-reviewed publications from Diabetes Care, The Lancet Diabetes & Endocrinology, and the Journal of Diabetes Investigation; regulatory information from the NMPA, PMDA, CDSCO, TGA, and HSA; epidemiological data from the WHO, International Diabetes Federation (IDF), CDC, and Global Burden of Disease Study; company annual reports, investor presentations, product portfolios, press releases, SEC filings, and official company websites of leading diabetes care device manufacturers.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling techniques and validated through multiple expert review and feedback loops to ensure accuracy and reliability.